{"protocolSection": {"identificationModule": {"nctId": "NCT03228017", "orgStudyIdInfo": {"id": "17-00692"}, "organization": {"fullName": "NYU Langone Health", "class": "OTHER"}, "briefTitle": "Subclinical Cardiovascular Disease in Psoriatic Disease", "officialTitle": "Subclinical Cardiovascular Disease in Psoriatic Disease"}, "statusModule": {"statusVerifiedDate": "2021-08", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2017-08-01", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2019-04-01", "type": "ACTUAL"}, "completionDateStruct": {"date": "2019-04-01", "type": "ACTUAL"}, "studyFirstSubmitDate": "2017-07-11", "studyFirstSubmitQcDate": "2017-07-19", "studyFirstPostDateStruct": {"date": "2017-07-24", "type": "ACTUAL"}, "resultsFirstSubmitDate": "2021-03-05", "resultsFirstSubmitQcDate": "2021-08-31", "resultsFirstPostDateStruct": {"date": "2021-09-28", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2021-08-31", "lastUpdatePostDateStruct": {"date": "2021-09-28", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "NYU Langone Health", "class": "OTHER"}}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": true, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "This study will look at how chronic inflammation seen in psoriatic disease translates into the increased atherosclerotic and thrombotic risk and how treatment reduces this CVD risk. The Aim of this study is to 1) Evaluate the association between moderate to severe psoriatic disease and measures of vascular function. 2) Evaluate the association between moderate to severe psoriatic disease and measures of thrombotic risk. 3) Understand how traditional medications used in cardiovascular disease (CVD) prevention such as aspirin and statins affect vascular function and thrombotic risk in those with moderate to severe psoriatic disease.", "detailedDescription": "Cardiovascular disease (CVD) remains the leading cause of death in the US. Five modifiable risk factors: smoking, hyperlipidemia, diabetes, hypertension and obesity, account for 50% of CVD mortality between the ages of 45 - 79.1 These traditional cardiac risk factors dictate who to treat with primary prevention measures but do not take into account patient-specific disease states such as psoriatic disease including psoriasis and psoriatic arthritis, which predispose to chronic inflammation. Patients with psoriatic disease have an increased risk of atherosclerotic heart disease and myocardial infarctions compared to matched controls."}, "conditionsModule": {"conditions": ["Cardiovascular Diseases", "Myocardial Infarction", "Atherosclerotic Cardiovascular Disease", "Thrombotic Vascular Disease"], "keywords": ["cardiovascular disease", "CVD"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "NON_RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 63, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Psoriatic Disease Patients", "type": "OTHER", "description": "Moderate to severe psoriatic disease", "interventionNames": ["Drug: Aspirin and/or Atorvastatin"]}, {"label": "Healthy Control", "type": "NO_INTERVENTION"}], "interventions": [{"type": "DRUG", "name": "Aspirin and/or Atorvastatin", "description": "This follow-up will allow us to assess how aspirin and/or atorvastatin affect platelet and endothelial function and inflammation.", "armGroupLabels": ["Psoriatic Disease Patients"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Mean Fold Change in Brachial Vein Endothelial Inflammatory Transcript", "description": "Endothelial sampling coupled to real-time PCR analysis will be used to monitor brachial vein endothelial inflammation", "timeFrame": "Baseline, 5 Months"}], "secondaryOutcomes": [{"measure": "Fold Change Change in Composite Endothelial Inflammation", "description": "Endothelial inflammation will be monitored after 2 weeks of aspirin 81mg therapy", "timeFrame": "Baseline (pre-Aspirin), 2 weeks (post-Aspirin)"}, {"measure": "Fold Change in Composite Endothelial Inflammation", "description": "Endothelial inflammation will be monitored after 2- weeks of 40mg of atorvastatin therapy.", "timeFrame": "Baseline (pre-Atorvastatin), 2 weeks (post-Atorvastatin)"}, {"measure": "Change in Levels of Circulating Thromboxane B2", "description": "Platelet activation is measured by levels of circulating thromboxane b2, which will be measured after 2- weeks of aspirin 81mg therapy", "timeFrame": "Baseline (pre-Aspirin), 2 weeks (post-Aspirin)"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Subjects with a history of moderate to severe psoriatic disease\n* Group 2: Healthy subjects without known psoriatic disease or cardiovascular disease\n\nExclusion Criteria:\n\n* Unable to speak Spanish or English\n* Active smoking (within the past year)\n* Autoimmune, rheumatologic or inflammatory disease which are not psoriasis or psoriatic arthritis\n* Known active cancer receiving treatment\n* Pregnancy\n* Anemia (hemoglobin \\< 9 mg/dl) or thrombocytopenia (Platelet count \\<75), or thrombocytosis (Platelet count \\>600)\n* A history of severe bleeding or bleeding disorders\n* Current medication use which interact with either aspirin or atorvastatin\n* Chronic kidney disease (CrCl \\< 30ml/min)\n* Congestive heart failure\n* Currently taking aspirin or a statin.\n* NSAID use within the past 48 hours", "healthyVolunteers": true, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "90 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Jeffrey Berger, MD", "affiliation": "NYU Langone Health", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "New York University School of Medicine", "city": "New York", "state": "New York", "zip": "10016", "country": "United States", "geoPoint": {"lat": 40.71427, "lon": -74.00597}}]}, "referencesModule": {"references": [{"pmid": "35490599", "type": "DERIVED", "citation": "Garshick MS, Block R, Drenkova K, Tawil M, James G, Brenna JT. Statin therapy upregulates arachidonic acid status via enhanced endogenous synthesis in patients with plaque psoriasis. Prostaglandins Leukot Essent Fatty Acids. 2022 May;180:102428. doi: 10.1016/j.plefa.2022.102428. Epub 2022 Apr 16."}, {"pmid": "32131611", "type": "DERIVED", "citation": "Garshick MS, Tawil M, Barrett TJ, Salud-Gnilo CM, Eppler M, Lee A, Scher JU, Neimann AL, Jelic S, Mehta NN, Fisher EA, Krueger JG, Berger JS. Activated Platelets Induce Endothelial Cell Inflammatory Response in Psoriasis via COX-1. Arterioscler Thromb Vasc Biol. 2020 May;40(5):1340-1351. doi: 10.1161/ATVBAHA.119.314008. Epub 2020 Mar 5."}, {"pmid": "30760013", "type": "DERIVED", "citation": "Garshick MS, Barrett TJ, Wechter T, Azarchi S, Scher JU, Neimann A, Katz S, Fuentes-Duculan J, Cannizzaro MV, Jelic S, Fisher EA, Krueger JG, Berger JS. Inflammasome Signaling and Impaired Vascular Health in Psoriasis. Arterioscler Thromb Vasc Biol. 2019 Apr;39(4):787-798. doi: 10.1161/ATVBAHA.118.312246."}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Psoriatic Disease Patients", "description": "Moderate to severe psoriatic disease\n\nAspirin and/or Atorvastatin: This follow-up will allow us to assess how aspirin and/or atorvastatin affect platelet and endothelial function and inflammation."}, {"id": "FG001", "title": "Healthy Control", "description": "Healthy Control"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "45"}, {"groupId": "FG001", "numSubjects": "18"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "45"}, {"groupId": "FG001", "numSubjects": "18"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Psoriatic Disease Patients", "description": "Moderate to severe psoriatic disease\n\nAspirin and/or Atorvastatin: This follow-up will allow us to assess how aspirin and/or atorvastatin affect platelet and endothelial function and inflammation."}, {"id": "BG001", "title": "Healthy Control", "description": "Healthy Control"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "45"}, {"groupId": "BG001", "value": "18"}, {"groupId": "BG002", "value": "63"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "45", "spread": "14.2"}, {"groupId": "BG001", "value": "40.5", "spread": "12.7"}, {"groupId": "BG002", "value": "42.75", "spread": "13.5"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "23"}, {"groupId": "BG001", "value": "8"}, {"groupId": "BG002", "value": "31"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "22"}, {"groupId": "BG001", "value": "10"}, {"groupId": "BG002", "value": "32"}]}]}]}, {"title": "Ethnicity (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "4"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "6"}]}, {"title": "Not Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "38"}, {"groupId": "BG001", "value": "15"}, {"groupId": "BG002", "value": "53"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "4"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "5"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "5"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "37"}, {"groupId": "BG001", "value": "12"}, {"groupId": "BG002", "value": "49"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "4"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "United States", "categories": [{"measurements": [{"groupId": "BG000", "value": "45"}, {"groupId": "BG001", "value": "18"}, {"groupId": "BG002", "value": "63"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Mean Fold Change in Brachial Vein Endothelial Inflammatory Transcript", "description": "Endothelial sampling coupled to real-time PCR analysis will be used to monitor brachial vein endothelial inflammation", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Fold Change", "timeFrame": "Baseline, 5 Months", "groups": [{"id": "OG000", "title": "Psoriatic Disease Patients", "description": "Moderate to severe psoriatic disease\n\nAspirin and/or Atorvastatin: This follow-up will allow us to assess how aspirin and/or atorvastatin affect platelet and endothelial function and inflammation."}, {"id": "OG001", "title": "Healthy Control", "description": "Healthy Control"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "45"}, {"groupId": "OG001", "value": "18"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "8.6", "spread": "8.6"}, {"groupId": "OG001", "value": "2.8", "spread": "2.2"}]}]}]}, {"type": "SECONDARY", "title": "Fold Change Change in Composite Endothelial Inflammation", "description": "Endothelial inflammation will be monitored after 2 weeks of aspirin 81mg therapy", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Full Range", "unitOfMeasure": "Fold Change", "timeFrame": "Baseline (pre-Aspirin), 2 weeks (post-Aspirin)", "groups": [{"id": "OG000", "title": "Psoriatic Disease Patients", "description": "Moderate to severe psoriatic disease\n\nAspirin and/or Atorvastatin: This follow-up will allow us to assess how aspirin and/or atorvastatin affect platelet and endothelial function and inflammation."}, {"id": "OG001", "title": "Healthy Control", "description": "Healthy Control"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "15"}, {"groupId": "OG001", "value": "15"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.28", "lowerLimit": "-0.4", "upperLimit": "-.15"}, {"groupId": "OG001", "value": "-0.04", "lowerLimit": "-0.17", "upperLimit": "0.09"}]}]}]}, {"type": "SECONDARY", "title": "Fold Change in Composite Endothelial Inflammation", "description": "Endothelial inflammation will be monitored after 2- weeks of 40mg of atorvastatin therapy.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Full Range", "unitOfMeasure": "Fold Change", "timeFrame": "Baseline (pre-Atorvastatin), 2 weeks (post-Atorvastatin)", "groups": [{"id": "OG000", "title": "Psoriatic Disease Patients", "description": "Moderate to severe psoriatic disease\n\nAspirin and/or Atorvastatin: This follow-up will allow us to assess how aspirin and/or atorvastatin affect platelet and endothelial function and inflammation."}, {"id": "OG001", "title": "Healthy Control", "description": "Healthy Control"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "20"}, {"groupId": "OG001", "value": "10"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.1", "lowerLimit": "-.21", "upperLimit": "-0.003"}, {"groupId": "OG001", "value": "0.1", "lowerLimit": "-.04", "upperLimit": "0.25"}]}]}]}, {"type": "SECONDARY", "title": "Change in Levels of Circulating Thromboxane B2", "description": "Platelet activation is measured by levels of circulating thromboxane b2, which will be measured after 2- weeks of aspirin 81mg therapy", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ng/ml", "timeFrame": "Baseline (pre-Aspirin), 2 weeks (post-Aspirin)", "groups": [{"id": "OG000", "title": "Psoriatic Disease Patients", "description": "Moderate to severe psoriatic disease\n\nAspirin and/or Atorvastatin: This follow-up will allow us to assess how aspirin and/or atorvastatin affect platelet and endothelial function and inflammation."}, {"id": "OG001", "title": "Healthy Control", "description": "Healthy Control"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "15"}, {"groupId": "OG001", "value": "15"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1", "spread": "0.8"}, {"groupId": "OG001", "value": "4.05", "spread": "3"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "timeFrame": "2 weeks", "eventGroups": [{"id": "EG000", "title": "Psoriatic Disease Patients", "description": "Moderate to severe psoriatic disease\n\nAspirin and/or Atorvastatin: This follow-up will allow us to assess how aspirin and/or atorvastatin affect platelet and endothelial function and inflammation.", "deathsNumAffected": 0, "deathsNumAtRisk": 45, "seriousNumAffected": 0, "seriousNumAtRisk": 45, "otherNumAffected": 0, "otherNumAtRisk": 45}, {"id": "EG001", "title": "Healthy Control", "description": "Healthy Control", "deathsNumAffected": 0, "deathsNumAtRisk": 18, "seriousNumAffected": 0, "seriousNumAtRisk": 18, "otherNumAffected": 0, "otherNumAtRisk": 18}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": true}, "pointOfContact": {"title": "Dr. Michael Garshick", "organization": "NYU Langone", "email": "michael.garshick@nyulangone.org", "phone": "212-263-0855"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot_SAP", "hasProtocol": true, "hasSap": true, "hasIcf": false, "label": "Study Protocol and Statistical Analysis Plan", "date": "2018-03-22", "uploadDate": "2021-03-05T14:38", "filename": "Prot_SAP_000.pdf", "size": 236812}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-07-01", "submissionTracking": {"firstMcpInfo": {"postDateStruct": {"date": "2021-04-01", "type": "ACTUAL"}}}}, "conditionBrowseModule": {"meshes": [{"id": "D000002318", "term": "Cardiovascular Diseases"}, {"id": "D000009203", "term": "Myocardial Infarction"}, {"id": "D000014652", "term": "Vascular Diseases"}, {"id": "D000050197", "term": "Atherosclerosis"}, {"id": "D000007238", "term": "Infarction"}], "ancestors": [{"id": "D000007511", "term": "Ischemia"}, {"id": "D000010335", "term": "Pathologic Processes"}, {"id": "D000009336", "term": "Necrosis"}, {"id": "D000017202", "term": "Myocardial Ischemia"}, {"id": "D000006331", "term": "Heart Diseases"}, {"id": "D000001161", "term": "Arteriosclerosis"}, {"id": "D000001157", "term": "Arterial Occlusive Diseases"}], "browseLeaves": [{"id": "M12155", "name": "Myocardial Infarction", "asFound": "Myocardial Infarction", "relevance": "HIGH"}, {"id": "M10282", "name": "Infarction", "asFound": "Infarction", "relevance": "HIGH"}, {"id": "M17400", "name": "Vascular Diseases", "asFound": "Vascular Disease", "relevance": "HIGH"}, {"id": "M26188", "name": "Atherosclerosis", "asFound": "Atherosclerotic Cardiovascular Disease", "relevance": "HIGH"}, {"id": "M10543", "name": "Ischemia", "relevance": "LOW"}, {"id": "M12284", "name": "Necrosis", "relevance": "LOW"}, {"id": "M6546", "name": "Coronary Artery Disease", "relevance": "LOW"}, {"id": "M19506", "name": "Myocardial Ischemia", "relevance": "LOW"}, {"id": "M9419", "name": "Heart Diseases", "relevance": "LOW"}, {"id": "M4469", "name": "Arteriosclerosis", "relevance": "LOW"}, {"id": "M4465", "name": "Arterial Occlusive Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000001241", "term": "Aspirin"}, {"id": "D000069059", "term": "Atorvastatin"}], "ancestors": [{"id": "D000000894", "term": "Anti-Inflammatory Agents, Non-Steroidal"}, {"id": "D000018712", "term": "Analgesics, Non-Narcotic"}, {"id": "D000000700", "term": "Analgesics"}, {"id": "D000018689", "term": "Sensory System Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000000893", "term": "Anti-Inflammatory Agents"}, {"id": "D000018501", "term": "Antirheumatic Agents"}, {"id": "D000005343", "term": "Fibrinolytic Agents"}, {"id": "D000050299", "term": "Fibrin Modulating Agents"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000010975", "term": "Platelet Aggregation Inhibitors"}, {"id": "D000016861", "term": "Cyclooxygenase Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}, {"id": "D000058633", "term": "Antipyretics"}, {"id": "D000000924", "term": "Anticholesteremic Agents"}, {"id": "D000000960", "term": "Hypolipidemic Agents"}, {"id": "D000000963", "term": "Antimetabolites"}, {"id": "D000057847", "term": "Lipid Regulating Agents"}, {"id": "D000019161", "term": "Hydroxymethylglutaryl-CoA Reductase Inhibitors"}], "browseLeaves": [{"id": "M4548", "name": "Aspirin", "asFound": "Baseline", "relevance": "HIGH"}, {"id": "M351", "name": "Atorvastatin", "asFound": "General", "relevance": "HIGH"}, {"id": "M4218", "name": "Anti-Inflammatory Agents, Non-Steroidal", "relevance": "LOW"}, {"id": "M4217", "name": "Anti-Inflammatory Agents", "relevance": "LOW"}, {"id": "M4032", "name": "Analgesics", "relevance": "LOW"}, {"id": "M20786", "name": "Analgesics, Non-Narcotic", "relevance": "LOW"}, {"id": "M20604", "name": "Antirheumatic Agents", "relevance": "LOW"}, {"id": "M8473", "name": "Fibrinolytic Agents", "relevance": "LOW"}, {"id": "M13865", "name": "Platelet Aggregation Inhibitors", "relevance": "LOW"}, {"id": "M19209", "name": "Cyclooxygenase Inhibitors", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}, {"id": "M29176", "name": "Antipyretics", "relevance": "LOW"}, {"id": "M4243", "name": "Anticholesteremic Agents", "relevance": "LOW"}, {"id": "M4278", "name": "Hypolipidemic Agents", "relevance": "LOW"}, {"id": "M4281", "name": "Antimetabolites", "relevance": "LOW"}, {"id": "M28883", "name": "Lipid Regulating Agents", "relevance": "LOW"}, {"id": "M21155", "name": "Hydroxymethylglutaryl-CoA Reductase Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Antipy", "name": "Antipyretics"}, {"abbrev": "Infl", "name": "Anti-Inflammatory Agents"}, {"abbrev": "ARhu", "name": "Antirheumatic Agents"}, {"abbrev": "FiAg", "name": "Fibrinolytic Agents"}, {"abbrev": "Analg", "name": "Analgesics"}, {"abbrev": "PlAggInh", "name": "Platelet Aggregation Inhibitors"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Lipd", "name": "Lipid Regulating Agents"}]}}, "hasResults": true}